Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa. Br J Dermatol 2019;181:609-611. [PMID: 30801662 DOI: 10.1111/bjd.17822] [Citation(s) in RCA: 60] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]

610 Secukinumab for patients with moderate-to-severe hidradenitis suppurativa. J Invest Dermatol 2018. [DOI: 10.1016/j.jid.2018.03.618] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]

Australia antigen testing for various blood products. THE JOURNAL OF THE ASSOCIATION OF PHYSICIANS OF INDIA 1985;33:499. [PMID: 4055674] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]